Ubs Group Ag Vectiv Bio Holding Ag Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2023 Aug 11, 2023	BUY	$8.29 - $16.97 $3.89 Million - $7.97 Million	469,471 Added 836.55%	525,591 $8.87 Million
Q1 2023 May 12, 2023	SELL	$7.34 - $9.15 $1.45 Million - $1.81 Million	-197,757 Reduced 77.89%	56,120 $477,000
Q4 2022 Feb 08, 2023	SELL	$7.79 - $8.98 $48,999 - $56,484	-6,290 Reduced 2.42%	253,877 $2.2 Million
Q3 2022 Nov 10, 2022	SELL	$4.7 - $6.07 $874 - $1,129	-186 Reduced 0.07%	260,167 $1.56 Million
Q2 2022 Aug 10, 2022	SELL	$4.2 - $6.55 $8,601 - $13,414	-2,048 Reduced 0.78%	260,353 $1.41 Million

Q1 2022 May 16, 2022	BUY	$4.6 - $5.8 $5,759 - $7,261	1,252 Added 0.48%	262,401 $1.24 Million
Q4 2021 Feb 14, 2022	BUY	$2.83 - $7.26 $1,842 - $4,726	651 Added 0.25%	261,149 $1.28 Million
Q3 2021 Nov 15, 2021	BUY	$6.7 - $11.54 $13,627 - $23,472	2,034 Added 0.79%	260,498 $2.01 Million
Q2 2021 Aug 13, 2021	BUY	$11.66 - $24.23 $3.01 Million - $6.26 Million	258,464 New	258,464 $3.01 Million

Others Institutions Holding VECT

# of Institutions

1

Shares Held

510K

Call Options Held

0

Put Options Held

0

Regency Capital Management Inc.\De

510K
Shares

$0
0.0% of portfolio

About VectivBio Holding AG

Ticker VECT
Exchange NASDAQ
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...

More about VECT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.